Page 186 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology PD-1/L1 inhibitors in advanced CC: Multicenter retro

Availability of data doi: 10.1200/jco.18.01265

Data will be made available on request. 11. Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab
plus anlotinib for PD-L1-positive recurrent or metastatic
References cervical cancer: A multicenter, single-arm, prospective
phase II trial. J Clin Oncol. 2022;40(16):1795-1805.
1. Zheng RS, Chen R, Han BF, et al. Cancer incidence and
mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. doi: 10.1200/jco.21.02091
2024;46(3):221-231. 12. Huang X, He M, Peng H, et al. Genomic profiling of advanced
doi: 10.3760/cma.j.cn112152-20240119-00035 cervical cancer to predict response to programmed death-1
inhibitor combination therapy: A secondary analysis of the
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics CLAP trial. J Immunother Cancer. 2021;9(5):e002223.
2022: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin. doi: 10.1136/jitc-2020-002223
2024;74(3):229-263. 13. Monk BJ, Colombo N, Tewari KS, et al. First-line
doi: 10.3322/caac.21834 pembrolizumab + chemotherapy versus placebo +
chemotherapy for persistent, recurrent, or metastatic cervical
3. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV cancer: Final overall survival results of KEYNOTE-826.
vaccination and cervical screening on cervical cancer
elimination: A comparative modelling analysis in 78 low- J Clin Oncol. 2023;41(36):5505-5511.
income and lower-middle-income countries. Lancet. doi: 10.1200/jco.23.00914
2020;395(10224):575-590.
14. Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab or
doi: 10.1016/s0140-6736(20)30068-4 placebo plus chemotherapy with or without bevacizumab
for persistent, recurrent, or metastatic cervical cancer:
4. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics
2020: GLOBOCAN estimates of incidence and mortality Subgroup analyses from the KEYNOTE-826 randomized
worldwide for 36 cancers in 185 countries. CA Cancer J Clin. clinical trial. JAMA Oncol. 2024;10(2):185-192.
2021;71(3):209-249. doi: 10.1001/jamaoncol.2023.5410
doi: 10.3322/caac.21660 15. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for
5. Wheeler CM. HPV genotypes: Implications for worldwide persistent, recurrent, or metastatic cervical cancer. N Engl J
cervical cancer screening and vaccination. Lancet Oncol. Med. 2021;385(20):1856-1867.
2010;11(11):1013-1014. doi: 10.1056/NEJMoa2112435
doi: 10.1016/s1470-2045(10)70249-7 16. Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor
6. The Lancet. Cervical cancer: Unequal progress. Lancet. CD28 is a primary target for PD-1-mediated inhibition.
2019;393(10167):104. Science. 2017;355(6332):1428-1433.
doi: 10.1016/s0140-6736(19)30003-0 doi: 10.1126/science.aaf1292
7. Mileshkin LR, Manoharan S. Improving survival from 17. Boussiotis VA. Molecular and biochemical aspects of the PD-1
metastatic, recurrent, or persistent cervical cancer. Lancet. checkpoint pathway. N Engl J Med. 2016;375(18):1767-1778.
2024;403(10421):2-4. doi: 10.1056/NEJMra1514296
doi: 10.1016/s0140-6736(23)02690-9 18. Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab
8. Mayadev JS, Ke G, Mahantshetty U, Pereira MD, Tarnawski R, or placebo with chemoradiotherapy followed by
Toita T. Global challenges of radiotherapy for the treatment pembrolizumab or placebo for newly diagnosed, high-risk,
of locally advanced cervical cancer. Int J Gynecol Cancer. locally advanced cervical cancer (ENGOT-cx11/GOG-
2022;32(3):436-445. 3047/KEYNOTE-A18): A randomised, double-blind, phase
3 clinical trial. Lancet. 2024;403(10434):1321-1332.
doi: 10.1136/ijgc-2021-003001
doi: 10.1016/s0140-6736(24)00317-9
9. Yusufaly TI, Zou J, Nelson TJ, et al. Improved prognosis of
treatment failure in cervical cancer with nontumor PET/CT 19. Abu-Rustum NR, Yashar CM, Arend R, et al. NCCN
radiomics. J Nucl Med. 2022;63(7):1087-1093. guidelines® insights: Cervical cancer, version 1.2024. J Natl
Compr Canc Netw. 2023;21(12):1224-1233.
doi: 10.2967/jnumed.121.262618
doi: 10.6004/jnccn.2023.0062
10. Chung HC, Ros W, Delord JP, et al. Efficacy and safety of
pembrolizumab in previously treated advanced cervical 20. Yang X, Zhang Y, Jia S, An J, Huang M. CALLA trial:
cancer: Results from the phase II KEYNOTE-158 study. Immunotherapy in locally advanced cervical cancer. Lancet
J Clin Oncol. 2019;37(17):1470-1478. Oncol. 2024;25(3):e95.

Volume 9 Issue 2 (2025) 178 doi:10.36922/ejmo.8074